Viva Biotech (01873) announced interim results. Adjusted net profit of 128 million yuan decreased by 30.08% year on year

Zhitongcaijing · 3d ago

According to Zhitong Finance App, Viva Biotech (01873) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 1,06.5 billion yuan, an increase of 20.99%; net profit of 100.9 million yuan, a decrease of 32.1%; adjusted non-IFRS net profit of 128 million yuan, a year-on-year decrease of 30.08%; and a basic profit of 0.04 yuan per share.

In the first half of 2026, the Group's net profit was $100.9 million, and adjusted non-IFRS net profit was $128 million, down from the same period last year. This is mainly due to the decline in investment income contributions during the reporting period, the adverse effects of changes in foreign exchange rates, and the increase in R&D expenses due to the layout of new businesses. However, the Group has always been convinced and confident that in the future, with the gradual digestion of short-term oppressive factors, considering the continuous recovery of the CRO business and the potential for the two commercial products of Langhua CDMO to be released one after another, combined with the potential of investment incubation companies, the Group's net profit will maintain an optimistic growth trend in the medium to long term.